Literature DB >> 14600784

Collagen turnover is diminished by different clones of skin fibroblasts from early- but not late-stage systemic sclerosis.

Camilo S Zurita-Salinas1, Edgar Krötzsch, Lino Díaz de León, Jorge Alcocer-Varela.   

Abstract

To investigate collagen turnover and proliferation in dermal fibroblasts from patients with systemic sclerosis (SSc) and their relationship with disease duration and cellular subpopulations, SSc patients were grouped by disease duration (less than 2.5 years or more than 7 years). Control and SSc fibroblasts were obtained from skin biopsies. Collagen biosynthesis was determined by [14C]-proline uptake. Type I/III collagens, gelatinolytic activity, and tissue inhibitors of metalloproteinases (TIMP)-1 and -2 were evaluated by electrophoresis, zymography, and enzyme-linked immunosorbent assay, respectively. Total collagen synthesis and the levels of alpha1(I), alpha2(I), and alpha1(III) chains, as well as TIMP-1 and proliferation were increased in fibroblasts only from patients with early-stage SSc. Gelatinolytic activity did not vary among the groups. This metabolic condition favors a higher local fibroblast population and is characterized by a heterogeneous clonal response in which the majority exhibited higher levels of collagen and TIMP-1 synthesis as well as an increase in their proliferation patterns involving hyper-reactive fibroblast subsets.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14600784     DOI: 10.1007/s00296-003-0364-6

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  42 in total

Review 1.  Growth factors, extracellular matrix, and oncogenes in scleroderma.

Authors:  S Gay; A Trabandt; L W Moreland; R E Gay
Journal:  Arthritis Rheum       Date:  1992-03

2.  Tissue inhibitors of matrix metalloendopeptidases.

Authors:  G Murphy; F Willenbrock
Journal:  Methods Enzymol       Date:  1995       Impact factor: 1.600

Review 3.  Matrix metalloproteinases: a review.

Authors:  H Birkedal-Hansen; W G Moore; M K Bodden; L J Windsor; B Birkedal-Hansen; A DeCarlo; J A Engler
Journal:  Crit Rev Oral Biol Med       Date:  1993

Review 4.  Systemic sclerosis.

Authors:  M I Perez; S R Kohn
Journal:  J Am Acad Dermatol       Date:  1993-04       Impact factor: 11.527

Review 5.  Evidence of fibroblast heterogeneity and the role of fibroblast subpopulations in fibrosis.

Authors:  K M Fries; T Blieden; R J Looney; G D Sempowski; M R Silvera; R A Willis; R P Phipps
Journal:  Clin Immunol Immunopathol       Date:  1994-09

6.  Scleroderma: increased biosynthesis of triple-helical type I and type III procollagens associated with unaltered expression of collagenase by skin fibroblasts in culture.

Authors:  J Uitto; E A Bauer; A Z Eisen
Journal:  J Clin Invest       Date:  1979-10       Impact factor: 14.808

7.  Elevated levels of human collagenase inhibitor in blister fluids of diverse etiology.

Authors:  H G Welgus; E A Bauer; G P Stricklin
Journal:  J Invest Dermatol       Date:  1986-11       Impact factor: 8.551

Review 8.  Systemic scleroderma. Clinical and pathophysiologic aspects.

Authors:  T Krieg; M Meurer
Journal:  J Am Acad Dermatol       Date:  1988-03       Impact factor: 11.527

9.  Increased biosynthesis of glycosaminoglycans by scleroderma fibroblasts in culture.

Authors:  R I Bashey; A Millan; S A Jimenez
Journal:  Arthritis Rheum       Date:  1984-09

10.  Serum tissue inhibitor of metalloproteinases in patients with systemic sclerosis.

Authors:  K Kikuchi; M Kubo; S Sato; M Fujimoto; K Tamaki
Journal:  J Am Acad Dermatol       Date:  1995-12       Impact factor: 11.527

View more
  3 in total

1.  Regional fibroblast heterogeneity in the lung: implications for remodeling.

Authors:  Chakradhar Kotaru; Kathryn J Schoonover; John B Trudeau; Mai-Lan Huynh; XiuXia Zhou; Haizhen Hu; Sally E Wenzel
Journal:  Am J Respir Crit Care Med       Date:  2006-03-16       Impact factor: 21.405

2.  Skin autofluorescence, as marker of accumulation of advanced glycation endproducts and of cumulative metabolic stress, is not increased in patients with systemic sclerosis.

Authors:  M E Hettema; H Bootsma; R Graaff; R de Vries; C G M Kallenberg; A J Smit
Journal:  Int J Rheumatol       Date:  2011-09-29

3.  Serum levels of tissue inhibitors of metalloproteinase 2 in patients with systemic sclerosis with duration more than 2 years: correlation with cardiac and pulmonary abnormalities.

Authors:  Amira Shahin; Amani Elsawaf; Shahira Ramadan; Olfat Shaker; Mona Amin; Mohamed Taha
Journal:  Mediators Inflamm       Date:  2006       Impact factor: 4.711

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.